<?xml version="1.0" encoding="UTF-8"?>
<ref id="ref33">
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Clark</surname>
    <given-names>M. P.</given-names>
   </name>
   <name>
    <surname>Ledeboer</surname>
    <given-names>M. W.</given-names>
   </name>
   <name>
    <surname>Davies</surname>
    <given-names>I.</given-names>
   </name>
   <name>
    <surname>Byrn</surname>
    <given-names>R. A.</given-names>
   </name>
   <name>
    <surname>Jones</surname>
    <given-names>S. M.</given-names>
   </name>
   <name>
    <surname>Perola</surname>
    <given-names>E.</given-names>
   </name>
   <etal/>
  </person-group>. (
  <year>2014</year>). 
  <article-title>Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2</article-title>. 
  <source>J. Med. Chem.</source>
  <volume>57</volume>, 
  <fpage>6668</fpage>â€“
  <lpage>6678</lpage>. 
  <pub-id pub-id-type="doi">10.1021/jm5007275</pub-id>, PMID: 
  <?supplied-pmid 25019388?>
  <pub-id pub-id-type="pmid">25019388</pub-id>
 </mixed-citation>
</ref>
